Soutrik BANERJEE

SDA homework 3 - 6th June 2006, 12:40 pm

1 (b)

Backward selection - I considered the **full model** with the variables (sans interactions):

age ivdrug cd4lt25 white basehgb proph karnof log_cfu ce cr

The parameter estimates (standard errors) in the **final model** are given below:

		Parameter	Standard		
Variable	DF	Estimate	Error	Chi-Square	Pr > ChiSq
cd41t25	1	0.96445	0.42138	5.2387	0.0221
karnof	1	-0.05573	0.01039	28.7828	<.0001
ce	1	1.22298	0.33832	13.0671	0.0003
cr	1	0.90165	0.33264	7.3473	0.0067
Var	iable	Hazard Ratio	Variable Label		
cd4. karı ce cr	lt25 nof	2.623 0.946 3.397 2.464	Baseline CD4<25 Karnofsky State Clarithromycin Clarithromycin	us Score + Ethambutol	

1 (a)

<u>Forward selection</u> - the results obtained were exactly same as in backward selection, *although SAS uses different methods for backward and forward selections*.

		Parameter	Standard		
Variable	DF	Estimate	Error	Chi-Square	Pr > ChiSq
cd41t25	1	0.96445	0.42138	5.2387	0.0221
karnof	1	-0.05573	0.01039	28.7828	<.0001
ce	1	1.22298	0.33832	13.0671	0.0003
cr	1	0.90165	0.33264	7.3473	0.0067
Var	iable	Hazard Ratio	Variable Label		
cd4 kar ce cr	lt25 nof	2.623 0.946 3.397 2.464	Baseline CD4<25 Karnofsky Statu Clarithromycin Clarithromycin	us Score + Ethambutol	

1(c)

<u>Stepwise selection</u> - the results obtained were exactly same as in backward (& forward) selection.

<u>Conclusion</u>: in the final model, Karnofsky score and CD4+ count are *protective* in terms of hazard ratios for overall survival as the endpoint. For the variables ce and cr, the interpretation is more complicated, since both variables simultaneously = 0 means 3 drug regimen. To note here that all patients received treatment with 2 or 3 drugs. Hence, the 3 drug regimen is associated with lower hazard than with each of the 2 drug regimens with the hazard ratios given in the tables above. All

the hazard ratios are based on the presence of other cofactors in the final models.

1 (d)
Score option (using best = 3 option):

Model (variables)	q	<i>X</i> ²	difference in df (from previous model)	difference in X ² (~ difference in - 2loglikelihood)	AIC	P
log_cfu cd4lt25 white karnof ce cr	6	41.48			566.6	
cd4lt25 white karnof ce cr	5	40.16	1	1.32	565.4	.25
cd4lt25 karnof ce cr	4	38.18	1	1.98	564.1	.16
karnof ce cr	3	32.86	1	5.32	567.1	.02

<u>Summary</u>: The model with 4 variables couldn't be reduced to model with 3 variables by both AIC and -2loglikelihood. By this approach, the final model is same as found with selection procedures above.

2 (Collett's approach to modelling PH model)

(a) Initial screening with all the univariate variables at slstay = 0.25 resulted in 5 variables being significant, viz., karnof, log_cfu , cd4lt25, white and ce as shown in the table below.

Z	Parameter estimates	Std. errors	P	-2loglikelihood	AIC
karnof	-0.04	0.01	<.0001	572.00	575.00
log_cfu	0.12	0.10	.25	589.08	592.08
cd4lt25	0.47	0.40	.24	588.86	591.86
white	0.32	0.25	.21	588.87	591.87
ce	0.50	0.26	0.06	586.74	589.74

(b) I used these 5 variables as main effects in my "full model" to reduce the model by backward selection. Slstay = 0.10 for main effects was chosen. At the end of the procedure, the variables log_cfu and white were removed.

Variable	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq
cd41t25	1	0.96337	0.42250	5.1991	0.0226
karnof	1	-0.05300	0.01035	26.2417	<.0001
ce	1	0.74690	0.26546	7.9164	0.0049
	Variable	Hazard Ratio	Variable La	oel	
	cd4lt25 karnof ce	2.621 0.948 2.110	Karnofsky S	4<25 (1=yes,0= tatus Score cin + Ethambut	•

```
AIC = 568.69; -2\loglikelihood = 559.69; q = 3 (\alpha = 3).
```

(c) Now, by doing forward selection in this model with other non-significant variables (of the univariate procedure) at slentry = 0.10. At the end of the procedure, the variable cr was added to the model 2 (b).

Variab	le DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq		
cd4lt2 karnof	-	0.96445 -0.05573	0.42138 0.01039	5.2387 28.7828	0.0221 <.0001		
ce	1	1.22298	0.33832	13.0671	0.0003		
cr	1	0.90165	0.33264	7.3473	0.0067		
	Variable	Hazard Ratio	Variable Label				
cd4lt25 2.623 karnof 0.946			Baseline CD4<25 (1=yes,0=no) Karnofsky Status Score				
ce 3.397			Clarithromycin + Ethambutol				
	cr	2.464	Clarithromycin + Rifabutin				
AIC =	AIC = 564.07 ; $-2\log$ likelihood = 552.07 ; $q = 4$ ($\alpha = 3$).						

(d) Now, I enter the stepwise reduction procedure with the model in 2 (c) with slentry and slstay, both, equal to 0.10 along with 5 interactions between cd4lt25 & ce, cd4lt25 & cr, karnof & ce, karnof & cr, cd4lt25 & karnof. The SAS codes are given below (the first 3 main effects are forced into the model, because karnof stays always in the final model):

```
/*changing 0 in categorical variables to 2*/
data mactrt2;
set mactrt;
if cd41t25=0 then cd41t25=2;
else cd4lt25=1;
if ce=0 then ce=2;
else ce=1;
if cr=0 then cr=2;
else cr=1;
run;
/*creating interaction variables*/
data mactrt3;
set mactrt2;
if cd4lt25=2 & ce=2 then cd4ce=0;
if cd4lt25=2 & ce=1 then cd4ce=1;
if cd4lt25=1 & ce=2 then cd4ce=2;
if cd4lt25=1 & ce=1 then cd4ce=3;
if cd4lt25=2 & cr=2 then cd4cr=0;
if cd4lt25=2 & cr=1 then cd4cr=1;
if cd4lt25=1 & cr=2 then cd4cr=2;
if cd4lt25=1 & cr=1 then cd4cr=3;
karn_ce=karnof*ce;
karn_cr=karnof*cr;
cd4_karn=cd4lt25*karnof;
title 'Collett stepwise selection';
proc phreg data=mactrt3;
  model survtime*survstat(0)=cd4lt25 ce cr karnof cd4ce cd4cr karn ce karn cr
```

cd4_karn / include=3 selection=stepwise slentry=0.1 slstay=0.1;
run;

2 4227		Parameter	Standard			
Variable	DF	Estimate	Error	Chi-Square	Pr > ChiSq	
cd4lt25	1	-0.96445	0.42138	5.2387	0.0221	
ce	1	-1.22298	0.33832	13.0671	0.0003	
cr	1	-0.90165	0.33264	7.3473	0.0067	
karnof	1	-0.05573	0.01039	28.7828	<.0001	
	Variable	Hazard Ratio	Variable Lal	bel		
	cd41t25	0.381	Baseline CD4	4<25 (1=yes,0=	no)	
	ce	0.294	Clarithromy	cin + Ethambut	ol	
	cr	0.406	Clarithromy	cin + Rifabuti	n	
karnof 0.946 Karnofsky Status Score						
AIC = 56	AIC = 564.07 ; $-2\log$ likelihood = 552.07 ; $q = 4$ ($\alpha = 3$).					

Summary:

The hazard ratios are changed from the first model, although the variables are the same at the end of model building by Collett's method. [This is because of the recoding of 0 values in the data step into 2 in order to avoid multiplication by 0 for the interaction variables.] One also finds that no interaction is retained in the final stepwise model by Collett's method. [Since no interaction was significant in the final model, the parameter estimates obtained by fitting the mactrt (original) data can be used in doing further analysis.]

3

Residual analysis:

The fit of the model (by Collett's method) was evaluated by plotting C-S and deviance residuals.

C—S Generalised residuals) 11s -1 -2 -3 -4 +++ ++ ++ -5 -7 -6 -5 -4 -3 -2 -1 10ggenr

Figure 1 showing Cox-Snell generalised residuals. X-axis shows log(survival), which are log(C-S residuals) or "pseudo/transformed" failure times; Y-axis shows log(-log(S(t))), which is

log(cumulative hazard). This should be a straight line passing through origin with a slope = 1. Apparently, it looks straight, except for the bottom right part.




Figure 2 showing deviance residuals against linear predictors (top left) and other covariates. The residuals apparently are distributed symmetrically on both sides of zero. (*The poor quality of images is regretted.*)

Influence diagnostics:

These are obtained by *dfbeta* and *ld* options in SAS. Deletion diagnostics means how much change will occur in the estimated parameter (beta_hat) when the *i*-th person was removed from the sample. The 5 smallest and largest values are provided by SAS (proc univariate). (*The tables are not presented here, but only a brief summary is mentioned*). The subject 140 was most influential in all the 4 covariates in the fitted model. Besides subjects 23 and 135 were also influential in the covariates *ce* and *cr*.

Subject 140 was again found to be most influential to cause change in -2loglikelihood.

Survival time for MAC patients

Log-log K-M estimates vs. log-time (by treatment)




Figure 3 showing log(-log(survival time)) [which is log(cumulative hazard)] vs. log(time) by treatment (3 arms). The curves cross, hence PH model may not hold, but that should be confirmed by a formal statistical test, for example, by "time*covariate" interaction (whether significant or not). This is done in the next exercise.

4 (b)

To test the PH assumption, I included time-varying covariates (already given in the dataset) as *cetime* and *crtime* (*ce* and *cr* varying with time, respectively).

The interaction of treatment and survival time is not significant (table below).

		Parameter	Standard		
Variable	DF	Estimate	Error	Chi-Square	Pr > ChiSq
cetime	1	-0.00359	0.00780	0.2120	0.6452
crtime	1	-0.01090	0.00740	2.1663	0.1411
cd41t25	1	0.82203	0.43045	3.6468	0.0562
karnof	1	-0.04508	0.01020	19.5243	<.0001
		Hazard			
	Variable	Ratio	Variable Lab	el	
	cetime	0.996			

<u>Summary</u>: The hazard ratio is constant (non-significant time-varying covariates) for the 3 treatment arms conditional on the covariates (*cd4lt25* and *karnof*). Therefore, a PH model is plausible in this case.

If we do not control for these covariates, the logrank test (proc lifetest) would be inappropriate for the analysis of the effect of treatment on survival time (as curves cross in Figure 3). One can therefore do a stratified analysis or include treatment by time interactions (extended Cox model).